These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 39388267)

  • 1. High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson's disease.
    Williams D; Glasstetter LM; Jong TT; Chen T; Kapoor A; Zhu S; Zhu Y; Calvo R; Gehrlein A; Wong K; Hogan AN; Vocadlo DJ; Jagasia R; Marugan JJ; Sidransky E; Henderson MJ; Chen Y
    Proc Natl Acad Sci U S A; 2024 Oct; 121(42):e2406009121. PubMed ID: 39388267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson's disease.
    Williams D; Glasstetter LM; Jong TT; Kapoor A; Zhu S; Zhu Y; Gehrlein A; Vocadlo DJ; Jagasia R; Marugan JJ; Sidransky E; Henderson MJ; Chen Y
    bioRxiv; 2024 Mar; ():. PubMed ID: 38712038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
    Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
    SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.
    Kopytova AE; Rychkov GN; Cheblokov AA; Grigor'eva EV; Nikolaev MA; Yarkova ES; Sorogina DA; Ibatullin FM; Baydakova GV; Izyumchenko AD; Bogdanova DA; Boitsov VM; Rybakov AV; Miliukhina IV; Bezrukikh VA; Salogub GN; Zakharova EY; Pchelina SN; Emelyanov AK
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of pyrimidinyl piperazines as non-iminosugar glucocerebrosidase (GCase) pharmacological chaperones.
    Hoshikawa T; Watanabe T; Kotake M; Tiberghien N; Woo CK; Lewis S; Briston T; Koglin M; Staddon JM; Powney B; Schapira AHV; Takle AK
    Bioorg Med Chem Lett; 2023 Feb; 81():129130. PubMed ID: 36640928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
    Kopytova AE; Rychkov GN; Nikolaev MA; Baydakova GV; Cheblokov AA; Senkevich KA; Bogdanova DA; Bolshakova OI; Miliukhina IV; Bezrukikh VA; Salogub GN; Sarantseva SV; Usenko TC; Zakharova EY; Emelyanov AK; Pchelina SN
    Parkinsonism Relat Disord; 2021 Mar; 84():112-121. PubMed ID: 33609962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Novel Human β-glucocerebrosidase Antibodies for Parkinson's Disease Research.
    Jong T; Gehrlein A; Sidransky E; Jagasia R; Chen Y
    J Parkinsons Dis; 2024; 14(1):65-78. PubMed ID: 38251062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation and Purification of ß-Glucocerebrosidase by Exploiting its Transporter LIMP-2 - Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease.
    Dobert JP; Bub S; Mächtel R; Januliene D; Steger L; Regensburger M; Wilfling S; Chen JX; Dejung M; Plötz S; Hehr U; Moeller A; Arnold P; Zunke F
    Adv Sci (Weinh); 2024 Jul; 11(25):e2401641. PubMed ID: 38666485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
    Menozzi E; Toffoli M; Schapira AHV
    Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease.
    Cyske Z; Gaffke L; Rintz E; Wiśniewska K; Węgrzyn G; Pierzynowska K
    Neurochem Int; 2024 Sep; 178():105774. PubMed ID: 38797393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
    Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
    Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease.
    Marano M; Zizzo C; Malaguti MC; Bacchin R; Cavallieri F; De Micco R; Spagnolo F; Bentivoglio AR; Schirinzi T; Bovenzi R; Ramat S; Erro R; Sorrentino C; Sucapane P; Pilotto A; Lupini A; Magliozzi A; Di Vico I; Carecchio M; Bonato G; Cilia R; Colucci F; Tamma F; Caputo E; Mostile G; Arabia G; Modugno N; Zibetti M; Ceravolo MG; Tambasco N; Cossu G; Valzania F; Manganotti P; Di Lazzaro V; Zappia M; Fabbrini G; Tinazzi M; Tessitore A; Duro G; Di Fonzo A
    Parkinsonism Relat Disord; 2024 Jul; 124():107023. PubMed ID: 38843618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.
    Jung O; Patnaik S; Marugan J; Sidransky E; Westbroek W
    Expert Rev Proteomics; 2016 May; 13(5):471-9. PubMed ID: 27098312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase.
    Goldin E; Zheng W; Motabar O; Southall N; Choi JH; Marugan J; Austin CP; Sidransky E
    PLoS One; 2012; 7(1):e29861. PubMed ID: 22272254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.
    Menozzi E; Schapira AHV
    CNS Drugs; 2020 Sep; 34(9):915-923. PubMed ID: 32607746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
    Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
    J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
    Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease.
    Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG
    Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.